Edition:
United States

CVS Health Corp (CVS.N)

CVS.N on New York Stock Exchange

82.44USD
28 Apr 2017
Change (% chg)

$-0.35 (-0.42%)
Prev Close
$82.79
Open
$82.79
Day's High
$82.86
Day's Low
$82.17
Volume
1,792,471
Avg. Vol
1,699,453
52-wk High
$106.67
52-wk Low
$69.30

Latest Key Developments (Source: Significant Developments)

CVS says specialty pharmacy services contract for Blue Cross, Blue Shield Federal Employee Program will terminate at end of 2017
Friday, 31 Mar 2017 09:57am EDT 

CVS Health Corp : CVS Health -confirmed that contract to provide specialty pharmacy services for Blue Cross, Blue Shield Federal Employee Program will terminate at end of 2017 . CVS Health Corp - given contract expires at year end, the loss of contract does not affect the company’s 2017 financial results .CVS Health Corp - loss of specialty pharmacy contract, is not expected to have a material impact on the company’s operating profit in 2018.  Full Article

Reynolds, State Officials and CVS Health announce availability of Naloxone at all CVS Pharmacy locations in Iowa
Wednesday, 29 Mar 2017 05:10pm EDT 

CVS Health Corp :CVS Health Corp - Iowa Lt. Gov. Kim reynolds, state officials and CVS Health announce availability of Naloxone at all CVS Pharmacy locations in Iowa.  Full Article

CVS Health reports Q4 adj. EPS $1.71
Thursday, 9 Feb 2017 06:55am EST 

Cvs Health Corp : Qtrly net revenues increased 11.7 pct to $46.0 billion . Qtrly adjusted EPS of $1.71 . Qtrly GAAP diluted EPS from continuing operations of $1.59 . Qtrly same store sales decreased 0.7 pct versus prior year, with pharmacy same store sales up 0.2 pct . 2017 guidance confirmed . Qtrly front store same store sales down 2.9 pct . Q1 earnings per share view $1.11 -- Thomson Reuters I/B/E/S . FY2017 earnings per share view $5.86 -- Thomson Reuters I/B/E/S . CVS Health reports record fourth quarter and full year results for 2016; confirms 2017 EPS guidance . Sees Q1 2017 adjusted earnings per share $1.07 to $1.13 . Sees FY 2017 adjusted earnings per share $5.77 to $5.93 . Sees FY 2017 GAAP earnings per share $5.02 to $5.18 . Pharmacy same store sales were negatively impacted for quarter by approximately 380 basis points due to recent generic introductions . Q4 earnings per share view $1.67 -- Thomson Reuters I/B/E/S . Q4 revenue view $46.50 billion -- Thomson Reuters I/B/E/S .In connection with anticipated store closures, company recorded a $34 million asset impairment charge in three months ended December 31, 2016.  Full Article

CVS Health 18 pct dividend increase for 2017
Thursday, 15 Dec 2016 07:30am EST 

Cvs Health Corp : Guidance for adjusted eps reaffirmed for 2016 and 2017 . Expect to deliver approximately $700 to $750 million in annual savings across enterprise by 2021 . CVS Health Corp - reaffirmed its previous cash flow outlook for 2016 . Board has approved an 18 percent increase in annual dividend in 2017, an increase that translates to $2.00 per share . CVS Health Corp - in 2017, company expects to deliver cash flow from operations of $7.7 billion to $8.6 billion . 18% dividend increase for 2017 . Gaap diluted eps is now expected to be in range of $4.82 to $4.88 in 2016 and $5.02 to $5.18 in 2017 . FY 2016 earnings per share view $5.81 -- Thomson Reuters I/B/E/S .FY 2017 earnings per share view $5.87 -- Thomson Reuters I/B/E/S.  Full Article

CVS says "Caught a little bit off guard" in bid process for Prime, TRICARE network
Tuesday, 8 Nov 2016 09:44am EST 

Cvs Health Corp : CVS Health executive says for Q4 2016 total same-store sales at retail are expected to be flat to down 1.75 percent -conf call . CVS Health executive says "For the fourth quarter, we expect enterprise revenues to be up 12.25 percent to 14 percent driven primarily by PBM growth" -conf call . Currently expect an increase in PBM EBIT of about 8 percent and the decrease in retail EBIT of about 8 percent in 2017 . Says "Caught a little bit off guard" in bid process for Prime and TRICARE network . CVS- Although both Omnicare, Target pharmacy acquisitions are performing well, ramp-up in level of accretion is slightly slower than anticipated . CVS Health- Given recent network changes it has become more difficult to grow share and therefore offset ongoing margin pressures in the near term . CVS - Maintaining 10 percent to 14 percent adjusted EPS growth rate annually off a larger base is becoming more challenging; now anticipate growth of about 10 percent on average . Expect annual EPS growth to generate to $7-$8 billion in free cash flow per year on average- conf call Further company coverage: [CVS.N] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

CVS Pharmacy announces voluntary withdrawal of homeopathic teething products
Friday, 30 Sep 2016 05:52pm EDT 

CVS Health Corp : Voluntary withdrawal being conducted in light of FDA's announcement recommending consumers stop using homeopathic teething products . CVS Pharmacy announces voluntary withdrawal of homeopathic teething products .A "do not sell" block has been placed in co's store register system to prevent further sale of any affected items.  Full Article

CVS Health sets quarterly dividend of $0.425 per share
Thursday, 22 Sep 2016 12:14pm EDT 

CVS Health Corp :Sets quarterly dividend of $0.425 per share.  Full Article

CVS Health makes overdose-reversal drug available without prescription in Colorado
Wednesday, 17 Aug 2016 09:30am EDT 

CVS Health Corp : Makes overdose reversal drug available without a prescription at all CVS pharmacy locations in Colorado .In addition to Colorado, CVS pharmacy locations in 30 other states able to dispense naloxone to patients without individual prescription.  Full Article

CVS Health Makes Overdose-Reversal Drug Naloxone Available Without A Prescription in Idaho
Friday, 12 Aug 2016 09:30am EDT 

CVS Health Corp :Opioid overdose-reversal medication Naloxone is now available without a prescription at CVS Pharmacy locations in Idaho.  Full Article

Concordia International confirms strategic review is ongoing
Wednesday, 3 Aug 2016 09:24am EDT 

Concordia International Corp : Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business . Confirmed that its review of strategic alternatives is ongoing and provided an update on its business . Concordia has no liquidity or debt issues . There was one formulary change affecting two products in its North America portfolio . CVS did not reimburse for nilandron at all in past three years and has reimbursed dutoprol twice in 2016 . Concordia International Corp. Confirms that strategic review is ongoing and provides update on its business . CVS Health confirmed that nilandron and dutoprol will be removed from CVS Health's formulary .Removal of treatments from cvs health's formulary is immaterial to business.  Full Article

More From Around the Web

DIARY-U.S. earnings week ahead

April 28 Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EST unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Event Name 01-May-2017 BMO AMG.N Affiliated Managers Group Inc Q1 2017 Affiliated Managers Group Inc Earnings Release 01-May-2017 BMO